Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) generates news primarily around the clinical and regulatory progress of GLSI-100, its investigational immunotherapy to prevent breast cancer recurrences, and the Phase III FLAMINGO-01 trial. Company press releases highlight milestones in patient screening and enrollment, preliminary clinical observations, regulatory designations, and trial expansion across the United States and Europe.
Readers following GLSI news can expect updates on FLAMINGO-01, including the number of patients screened, enrollment status in the HLA-A*02 and non-HLA-A*02 arms, and preliminary analyses of recurrence rates, immune responses, and safety. The company has reported that more than 1,000 patients have been screened and that the 250-patient non-HLA-A*02 open label arm is fully enrolled, with early analyses suggesting an approximately 80% reduction in recurrence rate after completion of the primary immunization series. These observations are described by the company as preliminary and subject to change as the trial matures.
News items also cover regulatory developments, such as the U.S. FDA granting Fast Track designation for GLSI-100 in the HLA-A*02 genotype population, and geographic expansion of FLAMINGO-01 into additional European countries, including Ireland, Portugal, Belgium, and Austria, following approvals from European regulators. Corporate strategy communications discuss clinical strategy, financing approaches such as at-the-market offerings, partnering activities, and oversight by the Data Safety Monitoring Board and Steering Committee.
For investors, clinicians, and observers, the GLSI news feed offers a consolidated view of how Greenwich LifeSciences describes the evolution of its lead program, including trial design refinements, interactions with regulators, and key governance decisions disclosed through SEC filings and press releases. Regularly reviewing these updates can help track the company’s reported progress in developing GLSI-100 for HER2-positive breast cancer patients.
Greenwich LifeSciences, Inc. (GLSI) announced that CEO Snehal Patel discussed the Phase IIb clinical trial of GLSI-100 in a recent TD Ameritrade interview. The trial revealed that 22.8% of 145 patients had an immune response to GP2 before treatment, indicating potential early recurrence of breast cancer. The forthcoming Phase III trial, named FLAMINGO-01, aims to explore this immunotherapy further. If successful, it could lead to significant advancements in breast cancer treatment. The trial is currently in the registration phase.
Greenwich LifeSciences (GLSI) reported promising results from the GP2 Phase IIb clinical trial at the San Antonio Breast Cancer Symposium 2021. The study observed that 22.8% of 145 patients had a positive immune response to GP2 prior to treatment, indicating potential for predicting breast cancer recurrence. While patients with a positive immune response recurred faster, the 5-year disease-free survival rate was 100% for HER2 positive patients treated with GP2. The company plans further studies to confirm findings and explore GP2 as a CAR-T therapy candidate.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announces participation in interviews and conferences centered around their immunotherapy, GLSI-100, aimed at preventing breast cancer recurrences. At the 2021 San Antonio Breast Cancer Symposium, management will present two posters. A key focus is the Phase IIb trial results indicating no recurrences over 5 years for treated HER2 positive patients. Upcoming virtual conferences include H.C. Wainwright BioConnect Conference and Biotech Showcase. The FLAMINGO-01 Phase III trial aims to enroll approximately 600 patients.
Greenwich LifeSciences (Nasdaq: GLSI) has appointed Dr. F. Joseph Daugherty as Medical Monitor for its upcoming Phase III clinical trial, named FLAMINGO-01, which aims to assess the immunotherapy GP2 for preventing breast cancer recurrences. The trial will involve approximately 600 patients with a primary focus on safety and efficacy, building on the success of a previous Phase IIb trial where no recurrences were observed in the HER2/neu 3+ population. The company emphasizes its commitment to rigorous safety oversight through Dr. Daugherty's extensive experience in oncology clinical trials.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced the commencement of commercial line filling for its immunotherapy GP2 aimed at preventing breast cancer recurrences. This milestone is part of preparations for filing a Biologics License Application (BLA) after generating three commercial lots, aiming to treat approximately 22,000 patients. The Phase III clinical trial, named FLAMINGO-01, will begin shortly, with a focus on patients with HLA-A*02. The company has engaged various partners for production and clinical support, enhancing the potential success of GP2 in the market.
Greenwich LifeSciences, Inc. (GLSI) will feature CEO Snehal Patel in an exclusive interview on Bloomberg TV's The RedChip Money Report on November 20, at 7 pm ET. The interview will cover Phase IIb clinical trial outcomes for GLSI-100, showing no metastatic breast cancer recurrences over five years. Upcoming clinical trials FLAMINGO-01 will involve 500 patients, aiming for significant event detection. The company is preparing for future data publications and highlights the impact of joining the Russell 2000.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced that CEO Snehal Patel will participate in Jefferies’ Annual London Healthcare Conference from November 16-19, 2021. This prestigious event is Europe's largest healthcare-focused conference, featuring top companies in the pharmaceutical and biotechnology sectors. The company is advancing its Phase III clinical trial, FLAMINGO-01, for GP2, an immunotherapy aimed at preventing breast cancer recurrence, with the trial expected to involve approximately 600 patients.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced the acceptance of two abstracts and posters for presentation at the San Antonio Breast Cancer Symposium (SABCS) scheduled for December 7-10, 2021. The posters will highlight data from their ongoing Phase IIb clinical trial of GLSI-100, their immunotherapy aimed at preventing breast cancer recurrence. CEO Snehal Patel emphasized the significance of this data, citing a 100% disease-free survival rate over five years. The Phase III trial, FLAMINGO-01, is set to commence, targeting approximately 500 patients.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) outlined progress on its Phase III clinical trial, FLAMINGO-01, aimed at evaluating GLSI-100, an immunotherapy for breast cancer recurrence prevention. The trial is now recruiting at over 15 large university hospitals. An open-label arm is introduced to broaden immune response data. Interim analysis is anticipated in about three years. The company is also advancing commercial manufacturing for potential regulatory submissions, enhancing prospects for conditional market approval based on positive interim findings.
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, has released an updated corporate presentation focused on GP2, an immunotherapy to prevent breast cancer recurrences. The presentation includes a combined analysis of 5-year Phase IIb data, showcasing no recurrences in patients treated with GP2. CEO Snehal Patel highlighted interest from major institutions for potential collaborations, licensing, and expansion of clinical trials in Europe. The company plans to commence a Phase III clinical trial following promising Phase IIb results, where GP2 was well-tolerated with no serious adverse events.